Destiny Pharma is attending the 7th Annual Microbiome Movement Drug Development Europe conference, in London, on 31 January-2 February 2023.
If you would like to meet with Destiny Pharma, please email us: conferences@destinypharma.com
Old events, meetings and conferences
Destiny Pharma is attending the 7th Annual Microbiome Movement Drug Development Europe conference, in London, on 31 January-2 February 2023.
If you would like to meet with Destiny Pharma, please email us: conferences@destinypharma.com
Destiny Pharma is attending the Biotech Showcase conference, in San Francisco, USA, on 9-11 January 2023.
If you would like to meet with Destiny Pharma, please email us: conferences@destinypharma.com
Destiny Pharma is attending the Inv€$tival Showcase 2022 conference, in London, UK, on 14 November 2022.
If you would like to meet with Destiny Pharma, please email us on conferences@destinypharma.com
Destiny Pharma is attending the Jefferies London Healthcare conference, in London, UK, on 15-17 November 2022.
If you would like to meet with Destiny Pharma, please email us on conferences@destinypharma.com
Destiny Pharma is attending the Microbiome Connect USA conference, in Boston, USA, on 16-17 November 2022.
If you would like to meet with Destiny Pharma, please email us on conferences@destinypharma.com
Destiny Pharma is presenting virtually at the BIO-Europe 2022 conference, in Leipzig, Germany, on 24-26 October 2022.
If you would like to meet with Destiny Pharma, please email us on conferences@destinypharma.com
Destiny Pharma is presenting virtually at the HC Wainwright 24th Annual Global Investment hybrid conference, in New York, USA, on 12-14 September 2022.
If you would like to meet with Destiny Pharma, please email us on conferences@destinypharma.com
Destiny Pharma are presenting at the 7th Microbiome Movement Drug Development 2022 conference in Boston on 21-24 June 2022.
If you would like to meet with Destiny Pharma, please email us on conferences@destinypharma.com
Data on lead program, NTCD-M3, is being presented at the prestigious Anaerobe 2022 Conference in Seattle, 29th July. Data indicates that NTCD-M3 will be effective alongside all antibiotics treating C.difficile infection. https://bit.ly/3zkJYrn
Destiny Pharma is attending the ID Week conference, in Washington DC, USA, on 19-23 October 2022.
If you would like to meet with Destiny Pharma, please email us on conferences@destinypharma.com